Population-level evidence: changes in nicotine markets and declines in smoking

Beyond individual cessation outcomes, a growing body of real-world evidence shows that shifts in national nicotine markets are associated with substantial declines in cigarette smoking at the population level [^1]. These trends are especially visible in countries where lower-risk nicotine products have become widely available and socially acceptable alternatives to smoking. In the United Kingdom, the rapid rise in adult vaping over the past decade has coincided with historic lows in smoking prevalence, including the first time that the number of people who vape exceeded the number who smoke [^2]. This transition has occurred alongside continued declines in youth smoking and without evidence of population-level renormalisation of smoking.

Sweden provides a longer-term example through the widespread use of snus. Sweden has one of the lowest smoking rates in Europe and correspondingly low rates of smoking-related disease among men, a pattern widely attributed to the displacement of cigarettes by snus rather than abstinence alone [^3].

In Japan, the introduction and rapid uptake of heated tobacco products (HTPs) has been associated with a sharp decline in cigarette sales, despite relatively stable overall nicotine use [^4]. This demonstrates that substitution within the nicotine market, rather than complete cessation, can still deliver substantial public health gains by reducing exposure to combustion-related toxins.

Taken together, these cases illustrate a critical point: changes in nicotine markets have public health consequences. When people who smoke switch from combustible cigarettes to substantially lower-risk products, population-level exposure to harm declines even if nicotine use persists. This challenges the assumption that reductions in smoking must be driven solely by abstinence-based cessation and highlights the importance of considering market dynamics, regulation, and product availability in tobacco control strategies.

For LMICs, where smoking cessation infrastructure is weak, these lessons are particularly relevant. Enabling regulated access to SNPs has the potential to accelerate declines in smoking-related disease at scale, provided that policies are proportionate, youth-protective, and grounded in accurate risk communication.